References
- Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:56–61.
- Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
- Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial – The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–2333.
- Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc of Hematol Educ Program. 2009;2009:385–395.
- Liersch R, Tidow CM, Berdel WE, et al. Prognostic factors for acute myeloid leukaemia in adults-biological significance and clinical use. Br J Haematol. 2014;165:17–38.
- Freireich EJ, Gehan EA, Sulmon D, et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593–608.
- Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendation of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649.
- Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and MD Anderson Cancer Center Study. J Clin Oncol. 2010;28:1766–1771.
- Yanada M, Borthakur G, Garcia-Manero G, et al. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res. 2008;32:1505–1509.
- Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258–1264.
- Zeidler L, Zimmmermann M, Moriche A, et al. Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica. 2012;97:402–409.
- Miraki-Moud F, Anjos-Afoso F, Hodby KA, et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci USA. 2013;110:13576–13581.
- Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104:630–639.
- Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64–70.
- Creutig U, Zimmermann M, Dworzak MN, et al. The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study relapsed AML 2001/01. Haematologica. 2014;99:1472–1478.
- Martin G, Barragan E, Bolufer P, et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Haematologica. 2000;85:699–703.
- Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia: a survey of 161 cases from the French AML intergroup. Blood. 2002;99:3517–3523.
- Dalley CD, Lister TA, Cavenagh JD, et al. Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia. Br J Cancer. 2001;84:147.